English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Pro

Presents the zaia usage as premium feature

ZAIA

Presents AI Discovery search usage as a premium feature

AI Discovery

Presents AI Discovery explain and summary usage as a premium feature

Content Analysis

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Presents the pdf analysis as premium feature

PDF Analysis

1500 Top-up

3000 Top-up

Zendy Basic

2500 Top-up

Zendy Unlimited

Presents the access of premium content as premium feature

Premium Content

The study aimed to evaluate the oncological outcomes related to bevacizumab-based combination therapy among patients with advanced or recurrent ovarian clear cell carcinoma (OCCC). PubMed, Web of Science, Cochrane Library and Embase were searched, and the Newcastle–Ottawa Scale (NOS) was utilized to assess the study quality. Results showed that bevacizumab significantly improved overall survival (OS) (HR = 0.51; 95% CI: 0.40–0.66) and progression-free survival (PFS) (HR = 0.42; 95% CI: 0.29–0.60). The overall objective response rate (ORR), complete response (CR), and partial response (PR) were 49% (95% CI: 39–60%), 17% (95% CI: 9–25%), and 31% (95% CI: 22–41%). Bevacizumab-based combination therapy may be a prospective strategy for advanced or recurrent OCCC.

cancer investigation

Systematic Review and Single-Arm Meta-Analysis of Bevacizumab Combined with Chemotherapy or Immunotherapy for Oncological Outcomes in Advanced/Recurrent Ovarian Clear Cell Carcinoma